Centaur Biopharma to manufacture COVID-19 vaccine for Vaxart

By The Science Advisory Board staff writers

October 7, 2020 -- Centaur Biopharmaceutical Services has expanded its manufacturing agreement with Vaxart to manufacture Vaxart's oral COVID-19 vaccine.

As a contract development and manufacturing organization, Centaur will provide its expertise in protein-based biologics and virus-based product manufacturing. The company, a subsidiary of KindredBio, has facilities in California and Kansas.

Under the terms of the extended agreement, Centaur will be responsible for scaling the COVID-19 clinical trial material into mid-size bioreactors at its California plant, and manufacturing at 2000-L scale in single-use bioreactors at its Kansas plant.

Vaxart received investigational new drug application clearance for its phase I clinical trial evaluating its oral COVID-19 vaccine candidate on September 14.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here